Medical Science 5
Why ASO Technology?
August 17, 2022
What makes ASO technology different?
What makes antisense oligonucleotides (ASOs) so special? Let’s first understand what an oligonucleotide is. An oligonucleotide is a short strand of synthetic DNA, or a nucleic-acid chain, usually consisting of up to approximately 20 nucleotides read from left to right. n-Lorem’s ASO technology is based on thirty years of innovation and investment to make ASOs drugs with optimal qualities. This technology is also uniquely beneficial for nano-rare patients due to its specificity and broad utility to address the myriad of mutations that nano-rare patients present. Each a unique program with a unique challenge.
Compared to other drug discovery platforms, discovering and developing an optimal ASO is inexpensive, quick and can be used to treat diseases that are caused by many different types of gene mutations. ASOs are designed to bind precisely with RNA, modifying the process of creating a disease-causing protein. Thereby making ASOs highly specific and a powerful drug discovery technology for nano-rare patients, who need a therapeutic approach that targets their specific gene mutation.
On This Episode We Discuss:
- The repurposing of small molecule drugs
- The potential of gene replacement therapy
- What makes ASO technology so special today?
- When did the drug development industry begin?
- Forming regulation: Changes in response to disaster
- The decentralization of the biotechnology industry
- Lessons to consider and challenges left to face
Watch on YouTube:
The host of the show is Dr. Stanley Crooke, a scientist, a physician, an entrepreneur and the father of antisense technology. Dr. Crooke is responsible for driving the development of antisense or ASO technology, an RNA-targeted technology responsible for the commercialization of three best- and first-in class medicines and more than 40 drugs in development. In 2020, Stan formed n-Lorem to use this powerful technology to develop experimental personalized ASO medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life.
Hosted by: Dr. Stan Crooke.
Videographer: Jon Magnuson of Mighty One Productions.
Producers: Kim Butler, Colin Delaney, Kira Dineen, Jon Magnuson, Andrew Serrano and Amy Williford
More from n-Lorem:
To continue this masterclass series, tune into the next lesson, Antisense (How We Do It at n-Lorem), releasing June 22, 2022. Listen to a brief preview here. You can stream other episodes on Apple Podcasts, Spotify, YouTube, nlorem.org, or any other podcast player by searching “n-Lorem”.
Listen to our next Intro to Medical Science episode
We cannot do
Together we are changing the world—
one patient at a time
We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.
Follow us on social for updates on our latest efforts